NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory COVID Protocol Might Inhibit SARS CoV-2 Replication Through Disruption of NF-κB Signaling

Résumé

Updated, peer reviewed and published https://link.springer.com/article/10.1007/s10787-021-00896-7#Sec7 In March 2020, I’ve sent a correspondence to NEJM (20-06753) calling the claims that led the world to avoid non-steroidal anti-inflammatory drugs in COVID-19 management as a scam and it was rejected by this journal as well as more than a dozen of other journals until published almost six months later at the reputable InflammoPharmacology. In April 2020, a concept paper was rapidly published as a letter to the editor favoring nitazoxanide over ivermectin for management of COVID-19 together with azithromycin. Since then, a protocol has evolved to safely manage dozens of pediatric, geriatric, adult and pregnant COVID-19 patients and it was rejected by dozens of journals since May 2020 (20-19376) and eventually it was published in August 2021 only after publishing several papers to justify its academic basis in highly reputable journals. I repeat my long-ignored claim NSAIDs/Nitazoxanide/Azithromycin immunomodulatory protocol (Kelleni’s Protocol) a game-changer that might end this pandemic safely and immediately and, in this manuscript, I’m adding more recent evidence that justify my claim.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0